- Home
- STEC vs TPST Comparison
STEC vs TPST Comparison
Compare STEC & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- TPST
- Stock Information
- Founded
- STEC 2006
- TPST 2011
- Country
- STEC China
- TPST United States
- Employees
- STEC N/A
- TPST N/A
- Industry
- STEC
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- TPST Health Care
- Exchange
- STEC NYSE
- TPST Nasdaq
- Market Cap
- STEC 29.7M
- TPST 33.0M
- IPO Year
- STEC 2021
- TPST N/A
- Fundamental
- Price
- STEC $0.97
- TPST $6.78
- Analyst Decision
- STEC
- TPST Hold
- Analyst Count
- STEC 0
- TPST 3
- Target Price
- STEC N/A
- TPST $30.00
- AVG Volume (30 Days)
- STEC 12.1K
- TPST 234.4K
- Earning Date
- STEC 07-01-2025
- TPST 08-07-2025
- Dividend Yield
- STEC N/A
- TPST N/A
- EPS Growth
- STEC N/A
- TPST N/A
- EPS
- STEC N/A
- TPST N/A
- Revenue
- STEC $28,023,000.00
- TPST N/A
- Revenue This Year
- STEC $9,392.20
- TPST N/A
- Revenue Next Year
- STEC N/A
- TPST N/A
- P/E Ratio
- STEC N/A
- TPST N/A
- Revenue Growth
- STEC 50.79
- TPST N/A
- 52 Week Low
- STEC $0.20
- TPST $5.35
- 52 Week High
- STEC $3.25
- TPST $35.23
- Technical
- Relative Strength Index (RSI)
- STEC 43.73
- TPST 46.00
- Support Level
- STEC $0.97
- TPST $6.48
- Resistance Level
- STEC $1.02
- TPST $7.04
- Average True Range (ATR)
- STEC 0.08
- TPST 0.84
- MACD
- STEC 0.00
- TPST -0.05
- Stochastic Oscillator
- STEC 14.78
- TPST 12.96
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.